Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thalassemia | 7 | 2015 | 267 | 0.650 |
Why?
|
Urinary Incontinence, Stress | 7 | 2016 | 180 | 0.640 |
Why?
|
Sample Size | 3 | 2015 | 845 | 0.550 |
Why?
|
Suburethral Slings | 6 | 2016 | 69 | 0.490 |
Why?
|
Hepatitis C, Chronic | 9 | 2011 | 1032 | 0.450 |
Why?
|
Interneurons | 5 | 2023 | 592 | 0.420 |
Why?
|
Survival Analysis | 3 | 2015 | 10092 | 0.370 |
Why?
|
Interferon-alpha | 6 | 2011 | 909 | 0.340 |
Why?
|
Polyethylene Glycols | 6 | 2011 | 1188 | 0.310 |
Why?
|
Biometry | 2 | 2008 | 571 | 0.300 |
Why?
|
Data Interpretation, Statistical | 2 | 2008 | 2698 | 0.300 |
Why?
|
Population Surveillance | 2 | 2008 | 2594 | 0.280 |
Why?
|
Models, Statistical | 4 | 2015 | 5098 | 0.280 |
Why?
|
Antiviral Agents | 9 | 2011 | 3070 | 0.270 |
Why?
|
HIV Infections | 8 | 2024 | 17542 | 0.270 |
Why?
|
Population Dynamics | 1 | 2008 | 314 | 0.270 |
Why?
|
beta-Thalassemia | 3 | 2013 | 234 | 0.260 |
Why?
|
Homosexuality, Male | 3 | 2024 | 1344 | 0.260 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2008 | 700 | 0.220 |
Why?
|
Analgesia, Patient-Controlled | 3 | 2013 | 117 | 0.220 |
Why?
|
Iron Chelating Agents | 3 | 2013 | 141 | 0.210 |
Why?
|
Urologic Surgical Procedures | 2 | 2016 | 281 | 0.210 |
Why?
|
Urethra | 2 | 2016 | 406 | 0.210 |
Why?
|
Liver Cirrhosis | 5 | 2011 | 1959 | 0.210 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2021 | 2204 | 0.200 |
Why?
|
Spironolactone | 3 | 2016 | 415 | 0.200 |
Why?
|
Mass Screening | 2 | 2008 | 5456 | 0.190 |
Why?
|
Schizophrenia | 4 | 2022 | 6977 | 0.190 |
Why?
|
Contact Tracing | 1 | 2003 | 274 | 0.190 |
Why?
|
Blood Group Incompatibility | 2 | 2012 | 134 | 0.180 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1639 | 0.180 |
Why?
|
Rwanda | 4 | 2024 | 671 | 0.170 |
Why?
|
Episode of Care | 1 | 2020 | 127 | 0.170 |
Why?
|
Anemia, Sickle Cell | 3 | 2013 | 1065 | 0.170 |
Why?
|
Neurofibromatosis 1 | 1 | 2024 | 561 | 0.160 |
Why?
|
Artifacts | 1 | 2007 | 1904 | 0.150 |
Why?
|
Papillomaviridae | 2 | 2024 | 1139 | 0.150 |
Why?
|
Ribavirin | 2 | 2010 | 395 | 0.150 |
Why?
|
Algorithms | 2 | 2008 | 14098 | 0.140 |
Why?
|
Urodynamics | 2 | 2016 | 349 | 0.140 |
Why?
|
Hearing Loss | 1 | 2024 | 785 | 0.140 |
Why?
|
Physical Therapy Modalities | 1 | 2020 | 533 | 0.140 |
Why?
|
Abortion, Induced | 1 | 2022 | 471 | 0.130 |
Why?
|
Erythrocyte Transfusion | 2 | 2012 | 575 | 0.130 |
Why?
|
Composite Resins | 1 | 2016 | 71 | 0.130 |
Why?
|
Anti-HIV Agents | 2 | 2023 | 4567 | 0.130 |
Why?
|
Pluripotent Stem Cells | 1 | 2023 | 808 | 0.130 |
Why?
|
Counseling | 1 | 2003 | 1553 | 0.130 |
Why?
|
Urination | 2 | 2015 | 204 | 0.130 |
Why?
|
Dental Restoration, Permanent | 1 | 2016 | 130 | 0.120 |
Why?
|
Program Evaluation | 1 | 2003 | 2505 | 0.120 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1856 | 0.120 |
Why?
|
North Carolina | 2 | 2007 | 329 | 0.120 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2011 | 2330 | 0.120 |
Why?
|
Cadherins | 1 | 2019 | 903 | 0.110 |
Why?
|
Biostatistics | 1 | 2015 | 162 | 0.110 |
Why?
|
Urinary Bladder, Overactive | 1 | 2015 | 117 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2015 | 10393 | 0.110 |
Why?
|
Stroke Volume | 4 | 2016 | 5618 | 0.110 |
Why?
|
Induced Pluripotent Stem Cells | 3 | 2020 | 1882 | 0.110 |
Why?
|
Hypertension, Pulmonary | 2 | 2015 | 1604 | 0.110 |
Why?
|
Cameroon | 2 | 2024 | 79 | 0.110 |
Why?
|
Siderophores | 1 | 2013 | 61 | 0.100 |
Why?
|
Pain | 3 | 2013 | 5101 | 0.100 |
Why?
|
Deferoxamine | 1 | 2013 | 155 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1405 | 0.100 |
Why?
|
Female | 48 | 2024 | 396660 | 0.100 |
Why?
|
Humans | 63 | 2024 | 767040 | 0.100 |
Why?
|
Phenols | 1 | 2016 | 526 | 0.100 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2012 | 99 | 0.100 |
Why?
|
Hemoglobin SC Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
Low Back Pain | 1 | 2020 | 989 | 0.100 |
Why?
|
Time Factors | 12 | 2020 | 40154 | 0.100 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 2030 | 0.100 |
Why?
|
Microglia | 1 | 2020 | 1370 | 0.090 |
Why?
|
Liver Neoplasms | 4 | 2011 | 4357 | 0.090 |
Why?
|
Penis | 2 | 2024 | 209 | 0.090 |
Why?
|
Anti-Retroviral Agents | 1 | 2021 | 1787 | 0.090 |
Why?
|
Male | 44 | 2024 | 364203 | 0.090 |
Why?
|
Adult | 34 | 2024 | 223317 | 0.090 |
Why?
|
Body Mass Index | 4 | 2024 | 13048 | 0.090 |
Why?
|
Arginine | 1 | 2015 | 931 | 0.090 |
Why?
|
Isoantibodies | 2 | 2012 | 681 | 0.090 |
Why?
|
Middle Aged | 37 | 2024 | 223233 | 0.090 |
Why?
|
Blood Group Antigens | 1 | 2012 | 183 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2023 | 12536 | 0.090 |
Why?
|
gamma-Globins | 1 | 2011 | 105 | 0.090 |
Why?
|
Prevalence | 7 | 2024 | 15851 | 0.090 |
Why?
|
Irritable Bowel Syndrome | 2 | 2006 | 454 | 0.090 |
Why?
|
Regression Analysis | 2 | 2020 | 6331 | 0.090 |
Why?
|
Sulfones | 1 | 2013 | 447 | 0.090 |
Why?
|
Stillbirth | 1 | 2013 | 381 | 0.090 |
Why?
|
Heart Failure | 4 | 2016 | 11877 | 0.080 |
Why?
|
Narcotics | 1 | 2012 | 332 | 0.080 |
Why?
|
Live Birth | 1 | 2013 | 516 | 0.080 |
Why?
|
Azacitidine | 1 | 2011 | 336 | 0.080 |
Why?
|
alpha-Thalassemia | 1 | 2009 | 53 | 0.080 |
Why?
|
Hemoglobins, Abnormal | 1 | 2009 | 119 | 0.080 |
Why?
|
Young Adult | 16 | 2024 | 59980 | 0.080 |
Why?
|
Quality of Life | 7 | 2016 | 13485 | 0.080 |
Why?
|
Urinary Incontinence | 1 | 2013 | 490 | 0.080 |
Why?
|
Students, Medical | 1 | 2022 | 1965 | 0.080 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 944 | 0.080 |
Why?
|
Mitochondria | 2 | 2020 | 3678 | 0.080 |
Why?
|
alpha-Fetoproteins | 1 | 2009 | 229 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2013 | 988 | 0.080 |
Why?
|
Cluster Analysis | 3 | 2016 | 2721 | 0.080 |
Why?
|
Prefrontal Cortex | 1 | 2019 | 2224 | 0.080 |
Why?
|
Computer Simulation | 2 | 2015 | 6260 | 0.070 |
Why?
|
Health Expenditures | 1 | 2020 | 2390 | 0.070 |
Why?
|
Collagen | 1 | 2016 | 2636 | 0.070 |
Why?
|
Pyridones | 1 | 2013 | 819 | 0.070 |
Why?
|
Antigens, Viral | 1 | 2011 | 994 | 0.070 |
Why?
|
Urinary Bladder | 1 | 2013 | 1155 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 645 | 0.070 |
Why?
|
Epilepsy | 1 | 2023 | 3317 | 0.070 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2011 | 361 | 0.070 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1171 | 0.070 |
Why?
|
Iron | 2 | 2013 | 1811 | 0.070 |
Why?
|
Hypertension | 2 | 2024 | 8615 | 0.070 |
Why?
|
Recombinant Proteins | 6 | 2011 | 6507 | 0.070 |
Why?
|
Coitus | 1 | 2007 | 132 | 0.070 |
Why?
|
Cholesterol, HDL | 1 | 2013 | 1816 | 0.070 |
Why?
|
Auranofin | 1 | 2005 | 16 | 0.060 |
Why?
|
Malawi | 1 | 2007 | 312 | 0.060 |
Why?
|
Analgesics, Opioid | 2 | 2013 | 3837 | 0.060 |
Why?
|
Hepatitis B | 1 | 2011 | 710 | 0.060 |
Why?
|
Data Collection | 1 | 2015 | 3321 | 0.060 |
Why?
|
Ventricular Function, Left | 2 | 2016 | 3934 | 0.060 |
Why?
|
Protein Precursors | 1 | 2009 | 1134 | 0.060 |
Why?
|
Adolescent | 14 | 2024 | 89046 | 0.060 |
Why?
|
Condoms | 1 | 2007 | 337 | 0.060 |
Why?
|
Echocardiography, Doppler | 3 | 2015 | 898 | 0.060 |
Why?
|
Risk Factors | 12 | 2024 | 74886 | 0.060 |
Why?
|
Disease Progression | 6 | 2011 | 13646 | 0.060 |
Why?
|
Activities of Daily Living | 1 | 2014 | 2429 | 0.060 |
Why?
|
Cerebral Cortex | 1 | 2020 | 5754 | 0.060 |
Why?
|
Employment | 1 | 2010 | 1110 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2015 | 14766 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2016 | 2085 | 0.060 |
Why?
|
North America | 3 | 2013 | 1287 | 0.060 |
Why?
|
Argentina | 2 | 2016 | 249 | 0.060 |
Why?
|
Health Promotion | 1 | 2016 | 2210 | 0.060 |
Why?
|
HIV-1 | 1 | 2021 | 6951 | 0.060 |
Why?
|
Audiometry | 1 | 2024 | 253 | 0.050 |
Why?
|
Liver | 4 | 2012 | 7578 | 0.050 |
Why?
|
Educational Status | 1 | 2010 | 2511 | 0.050 |
Why?
|
Fatty Liver | 1 | 2009 | 811 | 0.050 |
Why?
|
Sexual Behavior | 2 | 2010 | 2196 | 0.050 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26325 | 0.050 |
Why?
|
Piperazines | 1 | 2013 | 2548 | 0.050 |
Why?
|
AIDS Serodiagnosis | 1 | 2003 | 220 | 0.050 |
Why?
|
Vitamin D | 1 | 2016 | 3312 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5947 | 0.050 |
Why?
|
Acute Chest Syndrome | 2 | 2012 | 32 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 2 | 2012 | 70 | 0.050 |
Why?
|
Africa, Central | 1 | 2021 | 8 | 0.050 |
Why?
|
Multivariate Analysis | 5 | 2016 | 12069 | 0.050 |
Why?
|
Child, Preschool | 8 | 2024 | 42606 | 0.050 |
Why?
|
Sexually Transmitted Diseases | 1 | 2007 | 668 | 0.050 |
Why?
|
Abortion, Legal | 1 | 2022 | 121 | 0.050 |
Why?
|
Treatment Outcome | 11 | 2016 | 65295 | 0.040 |
Why?
|
Incidence | 4 | 2024 | 21526 | 0.040 |
Why?
|
Anus Diseases | 1 | 2020 | 53 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2013 | 15925 | 0.040 |
Why?
|
Penile Diseases | 1 | 2020 | 47 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2021 | 3232 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12250 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2011 | 2099 | 0.040 |
Why?
|
Child | 11 | 2024 | 80771 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3968 | 0.040 |
Why?
|
Intention | 1 | 2022 | 347 | 0.040 |
Why?
|
Comorbidity | 3 | 2024 | 10582 | 0.040 |
Why?
|
Follow-Up Studies | 7 | 2016 | 39317 | 0.040 |
Why?
|
Smoking | 1 | 2016 | 9081 | 0.040 |
Why?
|
Patient Dropouts | 1 | 2020 | 411 | 0.040 |
Why?
|
Aging | 2 | 2014 | 8729 | 0.040 |
Why?
|
Aged | 13 | 2021 | 171319 | 0.040 |
Why?
|
Registries | 1 | 2013 | 8351 | 0.030 |
Why?
|
Encephalitis | 1 | 2020 | 441 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2020 | 1337 | 0.030 |
Why?
|
Georgia (Republic) | 1 | 2016 | 39 | 0.030 |
Why?
|
Demography | 1 | 2021 | 1641 | 0.030 |
Why?
|
Valsalva Maneuver | 1 | 2016 | 99 | 0.030 |
Why?
|
United States | 9 | 2016 | 72971 | 0.030 |
Why?
|
HIV | 1 | 2023 | 1591 | 0.030 |
Why?
|
Blood Transfusion | 2 | 2013 | 1308 | 0.030 |
Why?
|
Antirheumatic Agents | 1 | 2005 | 1379 | 0.030 |
Why?
|
Incontinence Pads | 1 | 2015 | 2 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14672 | 0.030 |
Why?
|
Signal Transduction | 1 | 2019 | 23621 | 0.030 |
Why?
|
Russia | 1 | 2016 | 383 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2586 | 0.030 |
Why?
|
Arginase | 1 | 2015 | 81 | 0.030 |
Why?
|
Glutamic Acid | 1 | 2020 | 1182 | 0.030 |
Why?
|
Research Design | 2 | 2013 | 6210 | 0.030 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2020 | 1139 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2011 | 10254 | 0.030 |
Why?
|
Diagnostic Techniques, Urological | 1 | 2013 | 27 | 0.030 |
Why?
|
Cystoscopy | 1 | 2013 | 128 | 0.030 |
Why?
|
USSR | 1 | 2012 | 19 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2011 | 11923 | 0.030 |
Why?
|
Neurons | 2 | 2023 | 9517 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 244 | 0.030 |
Why?
|
Recovery of Function | 2 | 2013 | 2978 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2015 | 15824 | 0.030 |
Why?
|
Pressure | 1 | 2016 | 1172 | 0.030 |
Why?
|
Prognosis | 4 | 2016 | 29963 | 0.030 |
Why?
|
Mental Processes | 1 | 2014 | 242 | 0.030 |
Why?
|
Lebanon | 1 | 2013 | 246 | 0.030 |
Why?
|
Age Factors | 3 | 2015 | 18401 | 0.030 |
Why?
|
Urban Population | 1 | 2020 | 2044 | 0.020 |
Why?
|
Ontario | 1 | 2013 | 403 | 0.020 |
Why?
|
Life Style | 2 | 2015 | 3931 | 0.020 |
Why?
|
Tetanus Toxin | 1 | 2011 | 46 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2010 | 4855 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1250 | 0.020 |
Why?
|
Erythrocytes | 2 | 2011 | 2411 | 0.020 |
Why?
|
London | 1 | 2012 | 233 | 0.020 |
Why?
|
Hydromorphone | 1 | 2011 | 70 | 0.020 |
Why?
|
Hypercalciuria | 1 | 2011 | 31 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2011 | 189 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2012 | 5311 | 0.020 |
Why?
|
Candida | 1 | 2011 | 171 | 0.020 |
Why?
|
Office Visits | 1 | 2015 | 595 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2011 | 697 | 0.020 |
Why?
|
Hydroxyurea | 1 | 2012 | 284 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2127 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2013 | 551 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1824 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2016 | 12451 | 0.020 |
Why?
|
beta 2-Microglobulin | 1 | 2011 | 330 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2015 | 713 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2005 | 3778 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2011 | 415 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2014 | 1587 | 0.020 |
Why?
|
Seizures | 1 | 2023 | 2996 | 0.020 |
Why?
|
Bilirubin | 1 | 2011 | 440 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2011 | 685 | 0.020 |
Why?
|
Purines | 1 | 2013 | 614 | 0.020 |
Why?
|
Workplace | 1 | 2016 | 873 | 0.020 |
Why?
|
Independent Living | 1 | 2014 | 584 | 0.020 |
Why?
|
Splenectomy | 1 | 2011 | 390 | 0.020 |
Why?
|
Synapses | 1 | 2019 | 1759 | 0.020 |
Why?
|
India | 1 | 2016 | 2334 | 0.020 |
Why?
|
Prothrombin | 1 | 2009 | 194 | 0.020 |
Why?
|
Pulmonary Edema | 1 | 2012 | 408 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20169 | 0.020 |
Why?
|
Platelet Count | 1 | 2011 | 784 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2011 | 609 | 0.020 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2013 | 503 | 0.020 |
Why?
|
Pilot Projects | 2 | 2013 | 8732 | 0.020 |
Why?
|
Spirometry | 1 | 2012 | 928 | 0.020 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2012 | 418 | 0.020 |
Why?
|
Serum Albumin | 1 | 2011 | 676 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21178 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10748 | 0.020 |
Why?
|
Elephantiasis, Filarial | 1 | 2008 | 31 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7587 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 1733 | 0.020 |
Why?
|
Fluid Therapy | 1 | 2012 | 587 | 0.020 |
Why?
|
Proteinuria | 1 | 2011 | 613 | 0.020 |
Why?
|
Patient Preference | 1 | 2015 | 947 | 0.020 |
Why?
|
Morphine | 1 | 2011 | 658 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2658 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15645 | 0.020 |
Why?
|
Georgia | 1 | 2007 | 186 | 0.020 |
Why?
|
Albuminuria | 1 | 2011 | 658 | 0.020 |
Why?
|
Prospective Studies | 4 | 2013 | 54886 | 0.020 |
Why?
|
Infant | 2 | 2024 | 36485 | 0.020 |
Why?
|
Postoperative Care | 1 | 2013 | 1480 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 4054 | 0.020 |
Why?
|
Pregnancy | 2 | 2022 | 30238 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2227 | 0.020 |
Why?
|
Physical Examination | 1 | 2012 | 1265 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2024 | 81659 | 0.020 |
Why?
|
Memory Disorders | 1 | 2014 | 1193 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10622 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1326 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5875 | 0.020 |
Why?
|
Drug Utilization | 1 | 2012 | 1190 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15424 | 0.020 |
Why?
|
Blood Pressure | 1 | 2021 | 8531 | 0.020 |
Why?
|
Survival Rate | 2 | 2010 | 12823 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1916 | 0.020 |
Why?
|
Hemoglobins | 1 | 2011 | 1531 | 0.020 |
Why?
|
Cell Line | 1 | 2019 | 15567 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2012 | 2428 | 0.020 |
Why?
|
Long-Term Care | 1 | 2009 | 631 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2015 | 22254 | 0.010 |
Why?
|
Patient Compliance | 1 | 2015 | 2697 | 0.010 |
Why?
|
Cohort Studies | 3 | 2012 | 41718 | 0.010 |
Why?
|
Sex Distribution | 1 | 2009 | 2276 | 0.010 |
Why?
|
Depression | 2 | 2015 | 8234 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2476 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81912 | 0.010 |
Why?
|
Hepacivirus | 1 | 2010 | 1342 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2920 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2019 | 14476 | 0.010 |
Why?
|
Age Distribution | 1 | 2009 | 2870 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2011 | 1161 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2013 | 6310 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12790 | 0.010 |
Why?
|
Pain Measurement | 1 | 2013 | 3584 | 0.010 |
Why?
|
Fatigue | 1 | 2010 | 1556 | 0.010 |
Why?
|
RNA, Viral | 1 | 2010 | 2867 | 0.010 |
Why?
|
Autoantibodies | 1 | 2011 | 2114 | 0.010 |
Why?
|
Universities | 1 | 2007 | 1004 | 0.010 |
Why?
|
Peripheral Arterial Disease | 1 | 2013 | 1304 | 0.010 |
Why?
|
Viral Load | 1 | 2010 | 3385 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3488 | 0.010 |
Why?
|
Constipation | 1 | 2006 | 570 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2013 | 3618 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2006 | 1666 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2022 | 18063 | 0.010 |
Why?
|
Health Status | 1 | 2013 | 4091 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4256 | 0.010 |
Why?
|
Inpatients | 1 | 2012 | 2563 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13284 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6513 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2012 | 8535 | 0.010 |
Why?
|
Liver Transplantation | 1 | 2011 | 2416 | 0.010 |
Why?
|
Electrocardiography | 1 | 2012 | 6409 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2006 | 1069 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2015 | 59548 | 0.010 |
Why?
|
Diarrhea | 1 | 2006 | 1319 | 0.010 |
Why?
|
Obesity | 1 | 2021 | 13085 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6777 | 0.010 |
Why?
|
Animals | 2 | 2022 | 168965 | 0.010 |
Why?
|
Body Weight | 1 | 2009 | 4627 | 0.010 |
Why?
|
Risk Assessment | 2 | 2010 | 24299 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8504 | 0.010 |
Why?
|
Calcium | 1 | 2011 | 5792 | 0.010 |
Why?
|
Length of Stay | 1 | 2011 | 6489 | 0.010 |
Why?
|
Students | 1 | 2007 | 1744 | 0.010 |
Why?
|
DNA Methylation | 1 | 2011 | 4426 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 6000 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2011 | 10455 | 0.010 |
Why?
|
Databases, Factual | 1 | 2011 | 8068 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2010 | 7848 | 0.010 |
Why?
|
Brain | 1 | 2022 | 27163 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2011 | 11657 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 36582 | 0.000 |
Why?
|